Phase 2 N=150 Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Ovarian Cancer
Primary: Progression-free Survival (PFS) — 13.7; 8.4 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=95 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants
Phase 2 N=61 Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Ovarian Neoplasms
Primary: Objective Response Rate (ORR) Investigator Assessment: % of Patients in the Group Who Achieve a Complete Response(CR) or Partial Response(PR) According to RECIST…
Phase 2 N=22 Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Ovarian Cancer · Neoplasms, Ovarian
Primary: Number of Participants With the Indicated Response — 6; 11; 20; 7 participants
Phase 2 N=463 A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Ovarian Neoplasms · Ovarian Cancer
Primary: Objective Response Rate (ORR) — 27.66 Percentage of participants
Phase 3 N=266 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate (ORR) — 109; 37 Count of Participants — p=0.002
Phase 2 N=265 Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
Ovarian Cancer
Primary: Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) — 8.4; 4.8 Months — p=<0.00001
Phase 2 N=4 Dose-finding Study in Platinum-Resistant Ovarian Cancer
Recurrent Platinum-resistant Ovarian Cancer
Primary: Phase 1: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) of Grade Greater Than or Equal to (≥) 3 in Severity — 26; 12; 6; 1 Participants
Phase 2 N=3 Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma
Primary: Objective Response Rate (ORR) — 2; 0 Participants
Phase 2 N=122 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Phase 2 N=118 A Study LY2228820 for Recurrent Ovarian Cancer
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
Phase 2 N=40 Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants
Phase 2 N=50 Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Maximum Tolerated Dose (MTD) — 105 mg/m^2
Phase 2 N=110 BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Ovarian Neoplasms
Primary: Disease Control Rate (DCR) at Week 24 According to Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1 — 30.6; 43.1 percentage of participants
Phase 2 N=272 Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) — 69.3; 64.0…
Phase 2 N=20 Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
Ovarian Carcinoma · Peritoneal Neoplasms
Primary: Tumor Response Type: CR, PR, SD or PD — 1; 4; 9; 6 Participants
Phase 2 N=26 Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Clinical Benefit Rate [CBR] — 12 Participants
Phase 2 N=169 A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Ovarian Cancer
Primary: Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR) — 11.3; 13.0; 12.2; 6.9 Percentage of Participants
Phase 3 N=154 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Germline BRCA1/2 Mutations and · Metastatic Adenocarcinoma of the Pancreas
Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified…
Phase 3 N=442 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Ovarian Cancer
Primary: Progression-free Survival by Independent Review Committee — 3.5; 3.6 months — p=0.6294
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Phase 2 N=29 Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 3; 15; 5 Participants
Phase 3 N=831 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Genital Neoplasms, Female · Fallopian Tube Neoplasms · Ovarian Neoplasms
Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199
Phase 2 N=31 Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Recurrent Epithelial Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer
Primary: Overall Response Rate (ORR) — 4 participants
Phase 3 N=1,301 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Phase 2 N=51 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma · Recurrent Ovarian Carcinoma
Primary: Tumor Response — 23.4 Percentage of participants
Phase 2 N=86 Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
Ovarian Cancer · Primary Peritoneal Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin
Phase 3 N=553 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Ovarian Neoplasms · Platinum Sensitive Ovarian Cancer
Primary: Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA) — 21; 5.5 months — p=<0.0001
Phase 2 N=36 p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Phase 2 N=29 Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…